Table Info

Table 1.

Characteristics of study subjects

Parameters	Control group	Multiple sclerosis	P
N	22	24	Ns
Sex, N (%) Female ^b	16 (72.7%)	16 (66.6%)	Ns
Age in years ^a	38.4 ± 14	35.5 ± 10	Ns
Disease duration in years ^a	Na	15.9 ± 12.5	-
EDSS
Mild, N (%)	Na	17 (70.8%)	-
Moderate, N (%)	Na	4 (16.7%)	-
Severe, N (%)	Na	3 (12.5%)	-
Disease course
Relapsing-remitting, N (%)	Na	20 (83.3%)	-
Primary progressive, N (%)	Na	4 (16.7%)	-

^a Values expressed in mean ± standard deviation, student’s t-test; ^b values expressed in percentage, χ² test. Na: not applicable; Ns: non-significant (P > 0.05). Expanded disability status scale (EDSS) scores were categorized as mild, no to minimal disability (EDSS 0–2.5), moderate (EDSS 3–5), and severe (EDSS 5.5–10)

Declarations

Acknowledgments

We would like to thank Editage (www.editage.com.br) for English language editing.

Author contributions

PHVD: Investigation, Data curation, Writing—original draft. RPS: Investigation. PPC: Investigation, Conceptualization. JANM: Investigation, Conceptualization. CMOV: Conceptualization, Validation, Writing—review & editing, Supervision.

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures involving human participants performed in this study were in accordance with the ethical standards of the institutional and national research committee, were approved by Dr. Francisco das Chagas Lima and Silva Ethics Committee of Santa Casa Hospital of Belo Horizonte, Brazil (approval number 69385917.7.0000.5138), and complied with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent to participate

The informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

Some datasets generated and analyzed in this study are not publicly available but are available from the corresponding author upon reasonable request.

Funding

This study was supported by CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superio), CNPq (Conselho Nacional de Desenvolvimento Científico) and FAPEMIG (Fundação de Amparo à Pesquisa do Estado de Minas Gerais). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright

References

GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:269–85. [DOI] [PubMed] [PMC]

Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378:169–80. [DOI] [PubMed] [PMC]

Dobson R, Giovannoni G. Multiple sclerosis—a review. Eur J Neurol. 2019;26:27–40. [DOI] [PubMed]

Münzel EJ, Williams A. Promoting remyelination in multiple sclerosis-recent advances. Drugs. 2013;73:2017–29. [DOI] [PubMed] [PMC]

Tarlinton RE, Martynova E, Rizvanov AA, Khaiboullina S, Verma S. Role of Viruses in the Pathogenesis of Multiple Sclerosis. Viruses. 2020;12:643. [DOI] [PubMed] [PMC]

Donati D. Viral infections and multiple sclerosis. Drug Discov Today Dis Models. 2020;32:27–33. [DOI] [PubMed] [PMC]

Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13:25–36. [DOI] [PubMed]

De Silvestri A, Capittini C, Mallucci G, Bergamaschi R, Rebuffi C, Pasi A, et al. The Involvement of HLA Class II Alleles in Multiple Sclerosis: A Systematic Review with Meta-analysis. Dis Markers. 2019;2019:1409069. [DOI] [PubMed] [PMC]

Trapp BD, Nave K. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–69. [DOI] [PubMed]

10.

Dhib-Jalbut S, Arnold DL, Cleveland DW, Fisher M, Friedlander RM, Mouradian MM, et al. Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol. 2006;176:198–215. [DOI] [PubMed]

11.

Stadelmann C, Wegner C, Brück W. Inflammation, demyelination, and degeneration—recent insights from MS pathology. Biochim Biophys Acta. 2011;1812:275–82. [DOI] [PubMed]

12.

Hartung H, Aktas O, Menge T, Kieseier BC. Immune regulation of multiple sclerosis. Handb Clin Neurol. 2014;122:3–14. [DOI] [PubMed]

13.

Rosenthal AS. Immune Recognition. Ann Intern Med. 1975;83:445. [DOI]

14.

Frohman EM, Racke MK, Raine CS. Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med. 2006;354:942–55. [DOI] [PubMed]

15.

Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–76. [DOI] [PubMed]

16.

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285–94. [DOI] [PubMed]

17.

Hickman SJ, Kapoor R, Jones SJ, Altmann DR, Plant GT, Miller DH. Corticosteroids do not prevent optic nerve atrophy following optic neuritis. J Neurol Neurosurg Psychiatry. 2003;74:1139–41. [DOI] [PubMed] [PMC]

18.

Parry A, Corkill R, Blamire AM, Palace J, Narayanan S, Arnold D, et al. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol. 2003;250:171–8. [DOI] [PubMed]

19.

Masullo L, Papas MA, Cotugna N, Baker S, Mahoney L, Trabulsi J. Complementary and alternative medicine use and nutrient intake among individuals with multiple sclerosis in the United States. J Community Health. 2015;40:153–60. [DOI] [PubMed]

20.

Ren J, Fan C, Chen N, Huang J, Yang Q. Resveratrol pretreatment attenuates cerebral ischemic injury by upregulating expression of transcription factor Nrf2 and HO-1 in rats. Neurochem Res. 2011;36:2352–62. [DOI] [PubMed]

21.

Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G. Pleiotropic protective effects of phytochemicals in Alzheimer’s disease. Oxid Med Cell Longev. 2012;2012:386527. [DOI] [PubMed] [PMC]

22.

Yu Y, Wang R, Chen C, Du X, Ruan L, Sun J, et al. Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. J Psychiatr Res. 2013;47:315–22. [DOI] [PubMed]

23.

Rahman I, Biswas SK, Kirkham PA. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol. 2006;72:1439–52. [DOI] [PubMed]

24.

Gautam R, Jachak SM. Recent developments in anti-inflammatory natural products. Med Res Rev. 2009;29:767–820. [DOI] [PubMed]

25.

Jardim FR, de Rossi FT, Nascimento MX, da Silva Barros RG, Borges PA, Prescilio IC, et al. Resveratrol and Brain Mitochondria: a Review. Mol Neurobiol. 2018;55:2085–101. [DOI] [PubMed]

26.

Rauf A, Imran M, Butt MS, Nadeem M, Peters DG, Mubarak MS. Resveratrol as an anti-cancer agent: A review. Crit Rev Food Sci Nutr. 2018;58:1428–47. [DOI] [PubMed]

27.

Ko JH, Sethi G, Um JY, Shanmugam MK, Arfuso F, Kumar AP, et al. The Role of Resveratrol in Cancer Therapy. Int J Mol Sci. 2017;18:2589. [DOI] [PubMed] [PMC]

28.

Malaguarnera L. Influence of Resveratrol on the Immune Response. Nutrients. 2019;11:946. [DOI] [PubMed] [PMC]

29.

Bonnefont-Rousselot D. Resveratrol and Cardiovascular Diseases. Nutrients. 2016;8:250. [DOI] [PubMed] [PMC]

30.

Sawda C, Moussa C, Turner RS. Resveratrol for Alzheimer’s disease. Ann N Y Acad Sci. 2017;1403:142–9. [DOI] [PubMed] [PMC]

31.

Yang X, Xu S, Qian Y, Xiao Q. Resveratrol regulates microglia M1/M2 polarization via PGC-1α in conditions of neuroinflammatory injury. Brain Behav Immun. 2017;64:162–72. [DOI] [PubMed]

32.

Alrafas HR, Busbee PB, Nagarkatti M, Nagarkatti PS. Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells. J Leukoc Biol. 2019;106:467–80. [DOI] [PubMed] [PMC]

33.

Galiniak S, Aebisher D, Bartusik-Aebisher D. Health benefits of resveratrol administration. Acta Biochim Pol. 2019;66:13–21. [DOI] [PubMed]

34.

Pourhanifeh MH, Shafabakhsh R, Reiter RJ, Asemi Z. The Effect of Resveratrol on Neurodegenerative Disorders: Possible Protective Actions Against Autophagy, Apoptosis, Inflammation and Oxidative Stress. Curr Pharm Des. 2019;25:2178–91. [DOI] [PubMed]

35.

Chen X, Sun Z, Wang J, Liang W, Zhao X, Wang Y, et al. Predicting the Pharmacokinetic Characteristics of Edaravone Intravenous Injection and Sublingual Tablet Through Modeling and Simulation. Clin Ther. 2020;42:428–38. [DOI] [PubMed]

36.

Pervaiz S, Holme AL. Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal. 2009;11:2851–97. [DOI] [PubMed]

37.

Fu W, Zhuang W, Zhou S, Wang X. Plant-derived neuroprotective agents in Parkinson’s disease. Am J Transl Res. 2015;7:1189–202. [PubMed] [PMC]

38.

Ghaiad HR, Nooh MM, El-Sawalhi MM, Shaheen AA. Resveratrol Promotes Remyelination in Cuprizone Model of Multiple Sclerosis: Biochemical and Histological Study. Mol Neurobiol. 2017;54:3219–29. [DOI] [PubMed]

39.

Sahebkar A, Serban C, Ursoniu S, Wong ND, Muntner P, Graham IM, et al.; Lipid and Blood Pressure Meta-analysis Collaboration Group. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors—Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol. 2015;189:47–55. [DOI] [PubMed]

40.

Shindler KS, Ventura E, Dutt M, Elliott P, Fitzgerald DC, Rostami A. Oral resveratrol reduces neuronal damage in a model of multiple sclerosis. J Neuroophthalmol. 2010;30:328–39. [DOI] [PubMed] [PMC]

41.

Kouchaki E, Tamtaji OR, Salami M, Bahmani F, Daneshvar Kakhaki R, Akbari E, et al. Clinical and metabolic response to probiotic supplementation in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2017;36:1245–9. [DOI] [PubMed]

42.

Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377–82. [DOI] [PubMed]

43.

Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, et al. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 2005;49:495–504. [DOI] [PubMed]

44.

Tomé-Carneiro J, Larrosa M, Yáñez-Gascón MJ, Dávalos A, Gil-Zamorano J, Gonzálvez M, et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol Res. 2013;72:69–82. [DOI] [PubMed]

45.

Brasnyó P, Molnár GA, Mohás M, Markó L, Laczy B, Cseh J, et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr. 2011;106:383–9. [DOI] [PubMed]

46.

Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stødkilde-Jørgensen H, et al. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes. 2013;62:1186–95. [DOI] [PubMed] [PMC]

47.

Hsieh T, Wu JM. Resveratrol: Biological and pharmaceutical properties as anticancer molecule. Biofactors. 2010;36:360–9. [DOI] [PubMed] [PMC]

48.

Schnekenburger M, Dicato M, Diederich M. Plant-derived epigenetic modulators for cancer treatment and prevention. Biotechnol Adv. 2014;32:1123–32. [DOI] [PubMed]

49.

Weiskirchen S, Weiskirchen R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy? Adv Nutr. 2016;7:706–18. [DOI] [PubMed] [PMC]

50.

Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Deliv. 2014;11:1285–98. [DOI] [PubMed]

51.

Tomé-Carneiro J, Larrosa M, González-Sarrías A, Tomás-Barberán FA, García-Conesa MT, Espín JC. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr Pharm Des. 2013;19:6064–93. [DOI] [PubMed] [PMC]

52.

Baune BT. Inflammation and neurodegenerative disorders: is there still hope for therapeutic intervention? Curr Opin Psychiatry. 2015;28:148–54. [DOI] [PubMed]

53.

Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson’s disease and its potential as therapeutic target. Transl Neurodegener. 2015;4:19. [DOI] [PubMed] [PMC]

54.

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52. [DOI] [PubMed]

55.

Bicalho HM, Gontijo CM, Nogueira-Machado JA. A simple technique for simultaneous human leukocytes separation. J Immunol Methods. 1981;40:115–6. [DOI] [PubMed]

56.

Gonzaga RM, Volpe CMO, Villar-Delfino PH, Anjos PMF, Gomes PS, Nogueira-Machado JA. Resveratrol inhibits the production of reactive oxygen species in phorbol ester- and toll-like receptor-stimulated granulocytes from diabetic patients. J Diabetes Metab Disord Control. 2016;3:147–52. [DOI]

57.

Nauseef WM. Detection of superoxide anion and hydrogen peroxide production by cellular NADPH oxidases. Biochim Biophys Acta. 2014;1840:757–67. [DOI] [PubMed] [PMC]

58.

Freitas M, Lima JLFC, Fernandes E. Optical probes for detection and quantification of neutrophils’ oxidative burst. A review. Anal Chim Acta. 2009;649:8–23. [DOI] [PubMed]

59.

Dahlgren C, Karlsson A. Respiratory burst in human neutrophils. J Immunol Methods. 1999;232:3–14. [DOI] [PubMed]

60.

Lublin FD, Coetzee T, Cohen JA, Marrie RA, Thompson AJ; International Advisory Committee on Clinical Trials in MS. The 2013 clinical course descriptors for multiple sclerosis: A clarification. Neurology. 2020;94:1088–92. [DOI] [PubMed] [PMC]

61.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86. [DOI] [PubMed] [PMC]

62.

Angeloni C, Malaguti M, Barbalace MC, Hrelia S. Bioactivity of Olive Oil Phenols in Neuroprotection. Int J Mol Sci. 2017;18:2230. [DOI] [PubMed] [PMC]

63.

Padureanu R, Albu CV, Mititelu RR, Bacanoiu MV, Docea AO, Calina D, et al. Oxidative Stress and Inflammation Interdependence in Multiple Sclerosis. J Clin Med. 2019;8:1815. [DOI] [PubMed] [PMC]

64.

Siotto M, Filippi MM, Simonelli I, Landi D, Ghazaryan A, Vollaro S, et al. Oxidative Stress Related to Iron Metabolism in Relapsing Remitting Multiple Sclerosis Patients With Low Disability. Front Neurosci. 2019;13:86. [DOI] [PubMed] [PMC]

65.

Ibitoye R, Kemp K, Rice C, Hares K, Scolding N, Wilkins A. Oxidative stress-related biomarkers in multiple sclerosis: a review. Biomark Med. 2016;10:889–902. [DOI] [PubMed]

66.

Schwarz S, Leweling H. Multiple sclerosis and nutrition. Mult Scler. 2005;11:24–32. [DOI] [PubMed]

67.

Miller ED, Dziedzic A, Saluk-Bijak J, Bijak M. A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis. Nutrients. 2019;11:1528. [DOI] [PubMed] [PMC]

68.

Esposito S, Bonavita S, Sparaco M, Gallo A, Tedeschi G. The role of diet in multiple sclerosis: A review. Nutr Neurosci. 2018;21:377–90. [DOI] [PubMed]

69.

Shindler KS, Ventura E, Rex TS, Elliott P, Rostami A. SIRT1 activation confers neuroprotection in experimental optic neuritis. Invest Ophthalmol Vis Sci. 2007;48:3602–9. [DOI] [PubMed] [PMC]

70.

Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450:712–6. [DOI] [PubMed] [PMC]

71.

Vachharajani VT, Liu T, Wang X, Hoth JJ, Yoza BK, McCall CE. Sirtuins Link Inflammation and Metabolism. J Immunol Res. 2016;2016:8167273. [DOI] [PubMed] [PMC]

72.

Cho S, Chen JA, Sayed F, Ward ME, Gao F, Nguyen TA, et al. SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. J Neurosci. 2015;35:807–18. [DOI] [PubMed] [PMC]

73.

Lassmann H, van Horssen J. The molecular basis of neurodegeneration in multiple sclerosis. FEBS Lett. 2011;585:3715–23. [DOI] [PubMed]

74.

Arnold P, Mojumder D, Detoledo J, Lucius R, Wilms H. Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathways. Clin Pharmacol. 2014;6:35–42. [DOI] [PubMed] [PMC]

75.

van Horssen J, Witte ME, Schreibelt G, de Vries HE. Radical changes in multiple sclerosis pathogenesis. Biochim Biophys Acta. 2011;1812:141–50. [DOI] [PubMed]

76.

Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, et al. Oxidative damage in multiple sclerosis lesions. Brain. 2011;134:1914–24. [DOI] [PubMed] [PMC]

77.

Bae EH, Kim HY, Kang YU, Kim CS, Ma SK, Kim SW. Risk factors for in-hospital mortality in patients starting hemodialysis. Kidney Res Clin Pract. 2015;34:154–9. [DOI] [PubMed] [PMC]

78.

Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol. 1999;9:69–92. [DOI] [PubMed] [PMC]

79.

Miller E, Walczak A, Saluk J, Ponczek MB, Majsterek I. Oxidative modification of patient’s plasma proteins and its role in pathogenesis of multiple sclerosis. Clin Biochem. 2012;45:26–30. [DOI] [PubMed]

80.

Švajger U, Jeras M. Anti-inflammatory effects of resveratrol and its potential use in therapy of immune-mediated diseases. Int Rev Immunol. 2012;31:202–22. [DOI] [PubMed]

81.

Zhang S, Kan QC, Xu Y, Zhang GX, Zhu L. Inhibitory Effect of Matrine on Blood‐Brain Barrier Disruption for the Treatment of Experimental Autoimmune Encephalomyelitis. Mediators Inflamm. 2013;2013:736085. [DOI] [PubMed] [PMC]

82.

Floreani M, Napoli E, Quintieri L, Palatini P. Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sci. 2003;72:2741–50. [DOI] [PubMed]

83.

Leonard SS, Xia C, Jiang BH, Stinefelt B, Klandorf H, Harris GK, et al. Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun. 2003;309:1017–26. [DOI] [PubMed]

84.

Li Y, Cao Z, Zhu H. Upregulation of endogenous antioxidants and phase 2 enzymes by the red wine polyphenol, resveratrol in cultured aortic smooth muscle cells leads to cytoprotection against oxidative and electrophilic stress. Pharmacol Res. 2006;53:6–15. [DOI] [PubMed]

85.

Camandola S, Mattson MP. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin Ther Targets. 2007;11:123–32. [DOI] [PubMed]

86.

Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089–104. [DOI] [PubMed]

87.

Magliozzi R, Howell OW, Reeves C, Roncaroli F, Nicholas R, Serafini B, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol. 2010;68:477–93. [DOI] [PubMed]

88.

Magliozzi R, Serafini B, Rosicarelli B, Chiappetta G, Veroni C, Reynolds R, et al. B-cell enrichment and Epstein-Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2013;72:29–41. [DOI] [PubMed]

89.

Wang MJ, Huang HM, Hsieh SJ, Jeng KC, Kuo JS. Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol. 2001;112:28–34. [DOI] [PubMed]

90.

Zhu J, Yong W, Wu X, Yu Y, Lv J, Liu C, et al. Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun. 2008;369:471–7. [DOI] [PubMed]

91.

Bruner-Tran KL, Osteen KG, Taylor HS, Sokalska A, Haines K, Duleba AJ. Resveratrol inhibits development of experimental endometriosis in vivo and reduces endometrial stromal cell invasiveness in vitro. Biol Reprod. 2011;84:106–12. [DOI] [PubMed] [PMC]

92.

Wight RD, Tull CA, Deel MW, Stroope BL, Eubanks AG, Chavis JA, et al. Resveratrol effects on astrocyte function: relevance to neurodegenerative diseases. Biochem Biophys Res Commun. 2012;426:112–5. [DOI] [PubMed] [PMC]

93.

Wang D, Li SP, Fu JS, Zhang S, Bai L, Guo L. Resveratrol defends blood-brain barrier integrity in experimental autoimmune encephalomyelitis mice. J Neurophysiol. 2016;116:2173–9. [DOI] [PubMed] [PMC]

94.

Sato F, Martinez NE, Shahid M, Rose JW, Carlson NG, Tsunoda I. Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. Am J Pathol. 2013;183:1390–6. [DOI] [PubMed] [PMC]

95.

Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB. Interleukin-10 and related cytokines and receptors. Annu Rev Immunol. 2004;22:929–79. [DOI] [PubMed]

96.

Sawada M, Suzumura A, Hosoya H, Marunouchi T, Nagatsu T. Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J Neurochem. 1999;72:1466–71. [DOI] [PubMed]

97.

Matsumoto M, Baba A, Yokota T, Nishikawa H, Ohkawa Y, Kayama H, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. Immunity. 2014;41:1040–51. [DOI] [PubMed]

98.

Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002;3:944–50. [DOI] [PubMed]

99.

Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118:3420–30. [DOI] [PubMed] [PMC]

100.

Rojas OL, Pröbstel AK, Porfilio EA, Wang AA, Charabati M, Sun T, et al. Recirculating Intestinal IgA-Producing Cells Regulate Neuroinflammation via IL-10. Cell. 2019;176:610–24.e18. [DOI] [PubMed] [PMC]

101.

Wang P, Xie K, Wang C, Bi J. Oxidative stress induced by lipid peroxidation is related with inflammation of demyelination and neurodegeneration in multiple sclerosis. Eur Neurol. 2014;72:249–54. [DOI] [PubMed]